Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients

作     者：Li Liua Xiaolei Peia Runzhi Maa Yi Hea Rongli Zhanga Jialin Weia Qiaoling Maa Weihua Zhaia Aiming Pang Erlie Jiang Mingzhe Han Donglin Yang Sizhou Feng 

作者机构：Hematopoietic Stem Cell Transplantation CenterNational Clinical Research Center for Blood DiseasesState Key Laboratory of Experimental HematologyHaihe Laboratory of Cell EcosystemInstitute of Hematology&Blood Diseases HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeTianjin 300020China 

出 版 物：《Blood Science》 (血液科学（英文）)

年 卷 期：2023年第5卷第2期

页      面：106-110页

学科分类：1007[医学-药学(可授医学、理学学位)] 10[医学] 

基　　金：the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS)[2021-I2M-1-017]and[2021-I2M-C&T-B-080] Haihe Laboratory of Cell Ecosystem Innovation Fund[HH22KYZX0036] 

主　　题：Acute leukemia Antifungal prophylaxis Invasive fungal disease Itraconazole Posaconazole 

摘      要：Invasive fungal diseases(IFDs)are major and lethal infectious complications for patients with neutropenia after *** with intravenous and oral suspended itraconazole(200 mg Q12h intravenously×2 days followed by 5 mg/kg·d orally in twice)or oral suspension of posaconazole(200 mg Q8h)was administered for preventing *** only 2 episodes of proven IFDs were not included after propensity-score matching(PSM),while the incidence of possible IFDs was 8.2%(9/110)in itraconazole group and 1.8%(2/110)in posaconazole group,respectively(P=.030).In clinical failure analysis,the failure rate of posaconazole group was lower as compared to the itraconazole group(2.7%vs 10.9%,P=.016).Both intravenous-oral itraconazole and posaconazole suspension are effective in preventing IFDs,while posaconazole suspension seems more tolerable.